SynthesisOncoimmunology2020
Dose dependence of treatment-related adverse events for immune checkpoint inhibitor therapies: a model-based meta-analysis.
Synthesis in Oncoimmunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Applications of Model-Based Meta-Analysis in Drug Development.Pharmaceutical research · 2022Pooled it
- A model-based meta-analysis of immune-related adverse events during immune checkpoint inhibitors treatment for NSCLC.CPT: pharmacometrics & systems pharmacology · 2022Pooled it
- Tailored FcγR blockade enhances immune checkpoint therapy and overcomes resistance.Journal of experimental & clinical cancer research : CR · 2026Article
- Comparative outcomes with low-dose and standard-dose immune checkpoint inhibitors in microsatellite stable advanced gastric/gastroesophageal adenocarcinoma.ESMO gastrointestinal oncology · 2026Article
- Modeling exposure-driven adverse events of EGFR TKIs in the treatment of patients with non-small cell lung cancer.Acta pharmacologica Sinica · 2025Article
- Combination of racotumomab immunotherapy with programmed death-1 blockade in a preclinical model of non-small cell lung cancer.Translational lung cancer research · 2025Article
- Immune-related adverse events occurring rapidly after a single dose of immune checkpoint blockade.Journal for immunotherapy of cancer · 2025Article
- Real-world second-line treatment pattern for unresectable or advanced hepatic carcinoma in China: a retrospective database study.Journal of gastrointestinal oncology · 2025Article
- Application of Immune Checkpoint Inhibitors in Cancer.MedComm · 2025Review
- Partial Response to Nivolumab and Ipilimumab in a Patient With Malignant Pleural Mesothelioma and Pre-Existing Myasthenia Gravis Without Severe Flares or Immune-Related Adverse Events: A Case Report.Respirology case reports · 2025Article
- Tremelimumab plus Durvalumab prior to Chemoradiotherapy in Unresectable, Locally Advanced Non-Small Cell Lung Cancer: The Induction Trial.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Article
- Clinical outcomes after immune checkpoint inhibitor-associated acute kidney injury: a cohort study.BMJ open · 2025Article
- Hepatic Events During Immune Checkpoint Inhibitor Treatment Between Liver and Non-Liver Malignancies in Hepatitis B Endemic Areas.Alimentary pharmacology & therapeutics · 2025Article
- Toxicity Associated with Pembrolizumab Monotherapy in Patients with Gastrointestinal Cancers: A Systematic Review of Clinical Trials.Biomedicines · 2025Review
- Combination of PD-1/PD-L1 and CTLA-4 inhibitors in the treatment of cancer - a brief update.Frontiers in immunology · 2025Review
- Pharmacoeconomic evaluation of weight-based vs fixed-dose pembrolizumab for non-small cell lung cancer in China.Frontiers in immunology · 2025Article
- Therapeutic Immunomodulation of Tumor-Lymphatic Crosstalk via Intratumoral Immunotherapy.Molecular pharmaceutics · 2024Review
- Novel immunotherapeutic approaches in gastric cancer.Precision clinical medicine · 2024Review
- Nivolumab receptor occupancy on effector regulatory T cells predicts clinical benefit.Cancer science · 2024Article
- Mitigating non-genetic resistance to checkpoint inhibition based on multiple states of immune exhaustion.NPJ systems biology and applications · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Programmed cell death-1 (PD-1) and/or cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) immune checkpoint inhibitor (ICI) treatments are associated with adverse events (AEs), which may be dependent on ICI dose. Applying a model-based meta-analysis to evaluate safety data from published clinical trials from 2005 to 2018, we analyzed the dose/exposure dependence of ICI treatment-related AE (trAE) and immune-mediated AE (imAE) rates. Unlike with PD-1 inhibitor monotherapy, CTLA-4 inhibitor monotherapy exhibited a dose/exposure dependence on most AE types evaluated. Furthermore, combination therapy with PD-1 inhibitor significantly strengthened the dependence of trAE and imAE rates on CTLA-4 inhibitor dose/exposure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.